Pancreatic Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Pancreatic Cancer is a ~$7M Medicare Part D market with limited branded spend, driven by older cytotoxic agents and nascent targeted therapies.
Key Trends
- Gemcitabine (nucleoside analog) dominates but faces generic/biosimilar compression
- Paclitaxel (ABRAXANE) emerging as combination therapy backbone with $7M spend
- Early-stage bispecific and targeted programs (HER2/HER3, NRG1 fusion) entering clinical pipeline
Career Verdict
Pancreatic cancer remains a high-need specialty with limited commercial maturity; suited for specialists seeking R&D and clinical impact over near-term revenue upside.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ABRAXANE (paclitaxel albumin-bound) | Bristol Myers Squibb | $7M | 100% | Peak | Stable | 8.1yr |
Drug Class Breakdown
stable; entering LOE phase
generic erosion; multiple biosimilars/generics in market
minimal Medicare Part D penetration
early clinical stage; limited current market presence
Career Outlook
StablePancreatic cancer remains a high-unmet-need indication with a mature generic/biosimilar market for cytotoxics and an emerging precision medicine pipeline. Career growth will shift toward clinical development of targeted agents (NRG1, KRAS, HER2/HER3 programs) rather than branded chemotherapy commercialization. Positions in medical affairs, clinical operations, and early-phase trial management will see growing demand as the field transitions.
Breaking In
Entry-level professionals should seek roles in clinical operations or commercial medical affairs at large oncology platforms (J&J, AbbVie, AstraZeneca) to build oncology expertise; pancreatic-specific depth will grow as pipeline advances.
For Experienced Professionals
Experienced oncology professionals should prioritize early-phase programs and precision-medicine-focused companies to lead the transition from cytotoxic to targeted paradigms; this shift will define pancreatic cancer careers through 2030.
In-Demand Skills
Best For
Hiring Landscape
Pancreatic cancer hiring is anchored by large oncology platforms (J&J 1,373 jobs, AbbVie 1,051, AstraZeneca 1,029) rather than specialized pancreatic units. Commercial teams (1,469 roles) dominate, followed by manufacturing and clinical operations, reflecting mature chemotherapy supply chains and field-based sales models. Average salaries range $149K–$307K depending on department.
Top Hiring Companies
By Department
Broad oncology hiring at major biopharma firms offers stable career options; pancreatic-specific roles are absorbed into general oncology teams, creating less disease-area prestige but strong downstream career mobility.
On Market (4)
Approved therapies currently available
Competitive Landscape
138 companies ranked by most advanced pipeline stage
+108 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 17,950 patients across 50 trials
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
A Study of Ruxolitinib in Pancreatic Cancer Patients
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer
Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Chemotherapy With or Without Enoxaparin in Pancreatic Cancer
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Related Jobs in Oncology
Medical Director, Global Medical Affairs - Gastric/Pancreatic Cancer
Customer Service Representative
Sr. Account Manager - Molecular Instruments
Area Sales Manager
Data & AI Product Owner – Quality
Manufacturing Technician II, POROS Manufacturing (Rotating Weekends, Day Shift)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.